AVACTA presenting at Aacr11 Oct 2023 08:31
Hopefully Fiona has arrived safely in the United States of America. She will be showcasing Avactas latest therapeutic assets. These are on top of AVA3396.
THANK YOU FIONA
Abstract title: AVA3996, a novel pre|CISION(TM) medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein ("FAP") mediated cleavage to elicit tumor cell kill
Poster number: C169
Session: Poster Session C
Session date and time: Saturday, October 14 | 12:30 pm-4:00 pm
Session location: Level 2, Exhibit Hall D
Abstract title: A novel, tumor-targeted immunocytokine comprising an anti-PD-L1 Affimer(R) fused to IL-15 exhibits potent anti-tumor activity
Poster number: A077
Session: Poster Session A
Session date and time: Thursday, October 12 | 12:30 pm-4:00 pm
Session location: